Kimberly-Clark closes $48.7 billion Kenvue acquisition

Kimberly-Clark closed its purchase of Kenvue on November 2, 2026, roughly a year after agreeing to a cash-and-stock transaction with an enterprise value near $48.7 billion. The Dallas Business Journal said Kimberly-Clark is based in Irving. Each Kenvue share was swapped for $3.50 in cash and 0.14625 shares of Kimberly-Clark, a package valued at $21.01 per share at announcement. Holders who previously owned Kimberly-Clark stock control about 54% of the merged firm, while former Kenvue investors hold the remainder.

The transaction brings Huggies, Pull-Ups, Kleenex, Scott and Cottonelle together with Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno and Zyrtec. Deal documents show the merged business will generate roughly $32 billion in yearly revenue and $7 billion in adjusted EBITDA, with ten brands each topping $1 billion in sales across more than 175 countries.

The purchase closed after a turbulent stretch for Kenvue, which Johnson & Johnson separated into an independent company in 2023; its shares have lagged as the company faced lawsuits and a public dispute over Tylenol's safety. In October, President Trump urged pregnant women to avoid Tylenol, citing a connection between acetaminophen and autism that has not been proven. A few weeks later, Texas Attorney General Ken Paxton filed suit against both companies, claiming they concealed the drug's dangers and that J&J designed the 2023 separation to shield itself from liability. Kenvue rejected the autism allegations as misinformation and maintained that acetaminophen is still the safest painkiller for expectant mothers. The American College of Obstetricians and Gynecologists labeled the president's remarks irresponsible.

Closing paperwork indicates Kimberly-Clark used existing cash, new borrowings, and money from offloading a 51% interest in its International Family Care and Professional unit to cover the cash part of the deal. Startup Fortune interpreted the divestiture as a sign that Kimberly-Clark is ready to trim its overseas operations to gain size in North American consumer health, describing the 51% stake as a substantial part of its business being shed to finance the Kenvue acquisition.

The companies forecast $1.9 billion in expense reductions and an additional $500 million in sales, partially offset by $300 million of reinvestment, within four years after closing. Investors in both firms voted to approve the deal in January 2026, and Kimberly-Clark finalized it after securing the necessary regulatory approvals.

The completion does not eliminate Kenvue's legal exposure. At closing, Kenvue remained subject to lawsuits and political criticism over Tylenol, and the closing documents list litigation, regulatory probes, and indemnity commitments tied to Johnson & Johnson as risks to the merger and its integration.